These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 26581111)
1. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. Ohba F; Nomoto M; Hojo S; Akama H J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H; J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209 [TBL] [Abstract][Full Text] [Related]
4. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603 [TBL] [Abstract][Full Text] [Related]
5. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis. Furue M; Kadono T; Tsuji G; Nakahara T Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis. Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585 [No Abstract] [Full Text] [Related]
7. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial. Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S; J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371 [TBL] [Abstract][Full Text] [Related]
8. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Andoh T; Yoshida T; Kuraishi Y Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735 [TBL] [Abstract][Full Text] [Related]
9. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024 [TBL] [Abstract][Full Text] [Related]
11. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825 [TBL] [Abstract][Full Text] [Related]
12. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis. Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267 [TBL] [Abstract][Full Text] [Related]
13. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis. Purohit V; Riley S; Tan H; Ports WC J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779 [TBL] [Abstract][Full Text] [Related]
14. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice. Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Tom WL; Van Syoc M; Chanda S; Zane LT Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394 [TBL] [Abstract][Full Text] [Related]
16. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. Andoh T; Kuraishi Y J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881 [TBL] [Abstract][Full Text] [Related]
18. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial. Saeki H; Ito K; Yokota D; Tsubouchi H J Am Acad Dermatol; 2022 Mar; 86(3):607-614. PubMed ID: 34710557 [TBL] [Abstract][Full Text] [Related]